Assessment of Bone Health Education in US Multiple Myeloma and Solid Tumor Patients at Risk for Skeletal-Related Events
- PMID: 33935518
- PMCID: PMC8079256
- DOI: 10.2147/CMAR.S300063
Assessment of Bone Health Education in US Multiple Myeloma and Solid Tumor Patients at Risk for Skeletal-Related Events
Abstract
Purpose: Cancer patients with bone metastasis (BM) from solid tumors or multiple myeloma (MM) have an increased risk of painful skeletal-related events (SREs), which can decrease quality of life and increase mortality. Bone targeting agents (BTAs) can help delay or prevent SREs; however, a significant portion of eligible patients are not receiving BTA therapy. This study was conducted to understand patient awareness of cancer-related bone health and to identify opportunities to improve bone health education in cancer patients at risk of SREs.
Methods: The online BonE heAlth eduCatiOn Needs assessment (BEACON) survey included questions about patient demographics, cancer diagnosis and treatments (including BTA usage), and extent and satisfaction with bone health education received. Direct-to-patient outreach was used to recruit patients. Eligible patients were US adults with a diagnosis of self-reported MM or BM from a solid tumor (breast, lung, or prostate cancer) within the past three years.
Results: Of 125 patients, 71% were diagnosed with solid tumors with BM and 29% with MM. At least one prior SRE was experienced by 57% of patients (38% radiation to bone, 32% bone fracture, 22% spinal cord compression, and 19% surgery to bone), and 74% were currently receiving BTA therapy. Awareness of cancer bone health, protection strategies, and screening tests was low to moderate; patients were least informed of the impact of lifestyle changes (38%) and specific cancer treatments (≤35%) on bone health. Sixty-two percent of patients were not completely satisfied with the bone health education received. Patients generally wanted more information (58%) and to receive information by more than one mode of communication.
Conclusion: Notable gaps in bone health education were observed in cancer patients at risk for SREs indicating an important need for improved communication and education strategies to promote better health outcomes.
Keywords: bone metastasis; bone targeting agents; fracture; radiation to bone; spinal cord compression; surgery to bone.
© 2021 Flora et al.
Conflict of interest statement
Dr Darcy R Flora reports GRYT Health has received payment from Amgen to design, conduct, and analyze data from the study and to prepare the manuscript; GRYT Health also has received payment from Amgen for other research and for sponsorship of GRYT Health’s Global Virtual Cancer Conference. Dr Katherine B Carlson is a former employee of Amgen and is a current employee of Moderna. Dr Benoit Cadieux, Ms Jennifer Schenfeld, and Dr Kimberly A Lowe are employees of and hold stock in Amgen. The authors report no other conflicts of interest in this work.
Figures



Similar articles
-
Assessment of Bone Health Awareness and Education in Breast Cancer Patients with Bone Metastasis in the USA.J Cancer Educ. 2023 Oct;38(5):1522-1530. doi: 10.1007/s13187-023-02293-w. Epub 2023 Apr 28. J Cancer Educ. 2023. PMID: 37118404 Free PMC article.
-
Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach.J Bone Oncol. 2022 Mar 17;34:100423. doi: 10.1016/j.jbo.2022.100423. eCollection 2022 Jun. J Bone Oncol. 2022. PMID: 35378840 Free PMC article.
-
Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are naïve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events.Eur J Health Econ. 2021 Mar;22(2):243-254. doi: 10.1007/s10198-020-01247-z. Epub 2021 Jan 18. Eur J Health Econ. 2021. PMID: 33459901 Free PMC article. Clinical Trial.
-
Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.J Bone Oncol. 2022 Feb 7;33:100416. doi: 10.1016/j.jbo.2022.100416. eCollection 2022 Apr. J Bone Oncol. 2022. PMID: 35242510 Free PMC article. Review.
-
"The use of bisphosphonates to treat skeletal complications in solid tumours".Bone. 2021 Jun;147:115907. doi: 10.1016/j.bone.2021.115907. Epub 2021 Mar 4. Bone. 2021. PMID: 33676057 Review.
Cited by
-
A cross-sectional study on Chinese oncology nurses' knowledge of bone health among cancer patients.Support Care Cancer. 2023 Aug 1;31(8):501. doi: 10.1007/s00520-023-07966-2. Support Care Cancer. 2023. PMID: 37526757 Free PMC article.
-
Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study.Support Care Cancer. 2022 Nov;30(11):9267-9278. doi: 10.1007/s00520-022-07333-7. Epub 2022 Sep 6. Support Care Cancer. 2022. PMID: 36066628 Free PMC article.
-
Assessment of Bone Health Awareness and Education in Breast Cancer Patients with Bone Metastasis in the USA.J Cancer Educ. 2023 Oct;38(5):1522-1530. doi: 10.1007/s13187-023-02293-w. Epub 2023 Apr 28. J Cancer Educ. 2023. PMID: 37118404 Free PMC article.
References
-
- Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(8 Suppl):1588–1594. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous